Gilead’s Zydelig shows superior efficacy to Bendamustine/Rituximab in Phase 3 study
The DMC recommendation is based upon a predefined interim analysis indicating a statistically significant benefit in efficacy for progression-free survival (PFS) and overall survival (OS) in patients receiving